PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 3 months ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 3 months ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 1 year 4 months ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 1 year 4 months ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 4 months ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 4 months ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 1 year 4 months ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 1 year 4 months ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 4 months ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 4 months ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 09/12/2026 at 02:35, 11 hours 44 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 19 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 14 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 54 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 19 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 48 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 4 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 8 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 34 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 3 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report